{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-273416","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.643566+00:00","generated_at":"2026-05-16T22:21:52.614484+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Personalis receives Medicare coverage for NeXT Personal in breast cancer MRD surveillance","bullets":["CMS covers NeXT Personal Dx Breast MRD test for post-treatment surveillance of stage II/III breast cancer recurrence.","Reimbursement rate $3,878 for NeXT Personal Dx Breast MRD test; $1,158 for NeXT Personal Single Plasma Test.","Coverage effective retroactively from October 7, 2025; Single Plasma test available up to 6 years post-treatment.","Dx Breast MRD test covered once per cancer diagnosis; expands market access for Personalis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-273416","json":"https://secwatch.observer/filing/0001193125-25-273416.json","markdown":"https://secwatch.observer/filing/0001193125-25-273416.md","text":"https://secwatch.observer/filing/0001193125-25-273416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000119312525273416/0001193125-25-273416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000119312525273416/d158834d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:21:52.614484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}